On September 4, 2019 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported a late-breaker poster presentation at the upcoming 17th International Myeloma Workshop being held in Boston, Massachusetts from September 12-15, 2019 (Press release, Cellectar Biosciences, SEP 4, 2019, View Source [SID1234539262]). The data will focus on the activity of CLR 131 in a Phase 1, dose escalation study of patients with relapsed or refractory multiple myeloma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Late-Breaker poster presentation details

Poster Title: SP-305 CLR 131 Demonstrates High Rate of Activity in a Phase 1, Dose Escalation Study in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Session: Poster Session II
Date/Time: Saturday September 14, 2019 / 7:00am to 5:45pm
Location: Hynes Convention Center Hall C Level II

A copy of the presentation materials can be accessed on the Posters and Publications section of the Cellectar website once the presentation concludes.